Clinical Trials

Multiple clinical trials evaluating netupitant across Phase 1 and Phase 2 have been completed under industry sponsorship from entities including HK inno.N Corporation and Helsinn Healthcare SA. These studies primarily evaluated bioequivalence, safety, and pharmacokinetic and pharmacodynamic dose-finding in healthy participants as well as pediatric cancer patients at risk for chemotherapy-induced nausea and vomiting (CINV).

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04486157 Completed
Healthy
HK inno.N Corporation
 2021-03-18 Phase 1
NCT03204279 Completed
Chemotherapy-induced Nausea and Vomiting (CINV)
Helsinn Healthcare SA
 2017-08-31 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Netupitant product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Netupitant selectively binds to and inhibits the neurokinin 1 (NK1) receptor, blocking the binding of endogenous substance P and preventing downstream signal transduction pathways that mediate emetic signaling. By interrupting substance P-mediated neurotransmission within the central and peripheral nervous systems, netupitant suppresses the emetic reflex, thereby mitigating chemotherapy-induced nausea and vomiting in clinical settings.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.